Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rini BI et al. – Axitinib has antitumor activity in patients with mRCC refractory to prior VEGF–targeted therapy, including sorafenib. Toxicities were mild to moderate and were manageable. A randomized, phase III trial to compare axitinib with sorafenib in patients who have mRCC refractory to one prior first–line therapy regimen is underway.

Today in Pharmacology/kinetics...keeping you current

Medium-size-vessel vasculitis
Pediatric Nephrology, 12/04/09

Sirolimus and Cyclosporine A Alter Barrier Function In Renal Proximal Tubular Cells through Stimulation of ERK 1/2 Signaling and Claudin-1 Expression
American Journal of Physiology: Renal Physiology, 12/04/09

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Urologic Oncology: Seminars and Original Investigations, 12/03/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address